2. Signaling Pathways
  3. Apoptosis
  4. MDM-2/p53
  5. MDM-2/p53 Modulator

MDM-2/p53 Modulator

MDM-2/p53 Modulators (7):

Cat. No. Product Name Effect Purity
  • HY-158968
    MMs02943764
    		Modulator ≥98.0%
    MMs02943764 is a 1,2,4-triazole derivative with anticancer activity. MMs02943764 has significant antiproliferative effects on multiple cancer cell lines. PAC, a structural analog of MMs02943764, has significant cytotoxicity against the leukemia cell line K562 (IC50=35.264 μM), reduces the degradation of p53 by inhibiting Mdm2 and Pirh2, and induces K562 cell cycle arrest.
  • HY-145785A
    ADH-6 TFA
    		Modulator 99.91%
    ADH-6 TFA is a tripyridylamide compound. ADH-6 abrogates self-assembly of the aggregation-nucleating subdomain of mutant p53 DBD. ADH-6 TFA targets and dissociates mutant p53 aggregates in human cancer cells, which restores p53's transcriptional activity, leading to cell cycle arrest and apoptosis. ADH-6 TFA has the potential for the research of cancer diseases.
  • HY-145937
    PK9327
    		Modulator 98.50%
    PK9327 is a small-molecule stabilizer targeting cavity-creating p53 cancer mutations.
  • HY-145759
    Mutant p53 modulator-1
    		Modulator 98.25%
    Mutant p53 modulator-1 is a mutant p53 modulator. Mutant p53 modulator-1 reduces the progression of cancers that contain a p53 mutation (extracted from patent WO2021231474A1, compound 231B).
  • HY-156967
    BAY 1892005
    		Modulator 99.44%
    BAY 1892005 is a regulator of p53 protein and acts on p53 condensates without causing mutant p53 reactivation.
  • HY-145785
    ADH-6
    		Modulator
    ADH-6 is a tripyridylamide compound. ADH-6 abrogates self-assembly of the aggregation-nucleating subdomain of mutant p53 DBD. ADH-6 targets and dissociates mutant p53 aggregates in human cancer cells, which restores p53's transcriptional activity, leading to cell cycle arrest and apoptosis. ADH-6 has the potential for the research of cancer diseases[1].
  • HY-119948
    AKCI
    		Modulator
    AKCI is a type of AURKC-IκBα interaction inhibitor, with an IC50 value of 24.9 μM. In MDA-MB-231 cells, AKCI can induce G2/M cell cycle arrest by regulating the p53/p21/CDC2/cyclin B1 pathway, inhibit cell migration and invasion, and reduce colony formation and tumor growth. AKCI can be used for research on breast cancer.